{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypertension-in-pregnancy/prescribing-information/nifedipine/","result":{"pageContext":{"chapter":{"id":"80c4cdd6-918d-5b69-9052-a943de729d40","slug":"nifedipine","fullItemName":"Nifedipine","depth":2,"htmlHeader":"<!-- begin field 37bb9db5-fe24-4f36-8a64-ca6e28ea26c4 --><h2>Nifedipine</h2><!-- end field 37bb9db5-fe24-4f36-8a64-ca6e28ea26c4 -->","summary":"","htmlStringContent":"<!-- begin item 36d4bb0e-a726-4e6a-a8c2-05e21a184254 --><!-- end item 36d4bb0e-a726-4e6a-a8c2-05e21a184254 -->","topic":{"id":"6ecaddc4-ff30-5cf4-ad9e-1df6efa32f1b","topicId":"b42a4357-926e-40db-93be-eb2734585661","topicName":"Hypertension in pregnancy","slug":"hypertension-in-pregnancy","lastRevised":"Last revised in July 2020","chapters":[{"id":"be1a3062-ba16-5320-bc1f-7931438b3b5e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"37d79826-12c0-54a5-859c-f5aab239dccb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7ede8737-53eb-57a2-9db3-c67e7b595b36","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"000e1ae9-fec8-5c7e-93fa-aac37cbed3b1","slug":"changes","fullItemName":"Changes"},{"id":"6aee7a8f-5861-5cdc-98a3-6cca34fc56c0","slug":"update","fullItemName":"Update"}]},{"id":"a142cb05-c8c8-5f0b-a31f-aee4193f794a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fb45ed4d-238b-5c83-a4c9-503c743ce614","slug":"goals","fullItemName":"Goals"},{"id":"9fe5bf45-a5b8-5910-9d8c-6c7d392f1779","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"152c0aed-a09e-585e-be86-456cff579be0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e424db7c-6f59-5395-8125-3f64c8335e1c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"388966c0-e5d0-5421-b48f-b9c11780841e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"aa780aa5-6dd7-53a0-893d-5f60840b81a9","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"c2bcbadf-68d8-5fa9-8752-b5b9846e022a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"be8adaec-21d7-5658-acb7-9487648799b4","slug":"definition","fullItemName":"Definition"},{"id":"a31e2e01-f95d-55d6-a81d-9f251edbf121","slug":"prevalence","fullItemName":"Prevalence"},{"id":"fe25ef6b-b112-589a-aa03-6f59c10bb254","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d1cacb2e-13ff-5c3f-9767-77524f5938ad","slug":"prognosis","fullItemName":"Prognosis"},{"id":"5a7a190a-9065-5e86-a995-19f480ddc1ae","slug":"complications","fullItemName":"Complications"},{"id":"39c857d6-2892-50eb-926a-0e42813dfdc8","slug":"long-term-health-implications","fullItemName":"Long-term health implications"}]},{"id":"76ba09af-ee47-5bcc-9270-4189dc2521ea","fullItemName":"Management","slug":"management","subChapters":[{"id":"29858bb6-e45a-5a43-bcf6-707da3b7f93e","slug":"pre-eclampsia","fullItemName":"Scenario: Pre-eclampsia"},{"id":"a7e6503b-bdb3-5f87-8485-0352a165acbf","slug":"pre-existing-hypertension-or-hypertension-before-20-weeks","fullItemName":"Scenario: Pre-existing hypertension, or hypertension before 20 weeks"},{"id":"525f57d9-c730-5acb-bc09-7a9500642f44","slug":"new-hypertension-after-20-weeks","fullItemName":"Scenario: New hypertension after 20 weeks"},{"id":"4fae554e-dd42-5116-9621-ba14519b2cc7","slug":"proteinuria-no-hypertension-after-20-weeks","fullItemName":"Scenario: Proteinuria and no hypertension after 20 weeks"},{"id":"189d666f-8d4d-5259-9194-b51f622a899e","slug":"postpartum-follow-up","fullItemName":"Scenario: Postpartum follow-up"}]},{"id":"df72f6fc-57f8-59ce-863e-0aafbe952576","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d81aa3f7-0ac1-557e-aeb4-85c389e3d449","slug":"aspirin","fullItemName":"Aspirin"},{"id":"9c20faa9-01df-51f3-8ea5-1cff9dc7ba12","slug":"labetalol","fullItemName":"Labetalol"},{"id":"a8bfba7d-aa2a-58dd-8623-f94e9a11868e","slug":"methyldopa","fullItemName":"Methyldopa"},{"id":"80c4cdd6-918d-5b69-9052-a943de729d40","slug":"nifedipine","fullItemName":"Nifedipine"}]},{"id":"be2fc921-a370-593b-83f0-3adf0dbcb226","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4e8e53ad-14b2-51b1-b527-d41b79469ddf","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"766ae496-9560-5803-92fa-8d7f71dc073e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0306f0ee-51ab-53f0-bfba-47ceda06c33c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"204ea692-4044-51c2-b0d6-84f596e7ff27","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"fe018251-2fcc-5a91-9662-fd930649403a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"961ee437-62d3-5138-83b6-d59d61ff6085","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a96b6bfe-8e8a-51bd-beb4-c719aab1df08","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"df72f6fc-57f8-59ce-863e-0aafbe952576","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"cbeb63a7-6dc0-57ca-b65b-c15db05d5922","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field f42f811a-50f0-40b1-8efc-46fd02a292fc --><h3>Contraindications and cautions</h3><!-- end field f42f811a-50f0-40b1-8efc-46fd02a292fc -->","summary":"","htmlStringContent":"<!-- begin item 461a7111-32b4-4226-b9cc-8d586b9f9a29 --><!-- begin field 9ff9200d-0ac8-411c-94c5-ee113c32df49 --><ul><li>Nifedipine is not specifically licensed for the treatment of hypertension in pregnancy.</li></ul><p><strong>Nifedipine should not be prescribed to people with:</strong></p><ul><li>Cardiogenic shock.</li><li>Clinically significant aortic stenosis.</li><li>Unstable or acute angina.</li><li>Recent history (within 4 weeks) of myocardial infarction.</li></ul><p><strong>Nifedipine should be used with caution in people with:</strong></p><ul><li>Severe hypotension (systolic blood pressure less than 90 mmHg).</li><li>Hepatic impairment.</li><li>Poor cardiac reserve.</li><li>Diabetes mellitus — may require adjustment of diabetes treatment as nifedipine can affect blood sugar.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 9ff9200d-0ac8-411c-94c5-ee113c32df49 --><!-- end item 461a7111-32b4-4226-b9cc-8d586b9f9a29 -->","subChapters":[]},{"id":"2fe9fc69-b53e-52b8-a76c-98f22cabbf32","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field fdd27eaf-4fd0-4567-afd2-1b4c6ca87afb --><h3>Adverse effects</h3><!-- end field fdd27eaf-4fd0-4567-afd2-1b4c6ca87afb -->","summary":"","htmlStringContent":"<!-- begin item 0b6599db-45c6-47e7-8071-bf334f393056 --><!-- begin field ca206982-10cf-4c99-93c5-d616e185f784 --><p><strong>Adverse effects of nifedipine include:</strong></p><ul><li>Neurological — headache, migraine, paraesthesia, tremor, asthenia, vertigo, visual disturbance.</li><li>Cardiac — vasodilation, hypotension, palpitations, dizziness, tachycardia, syncope.</li><li>Gastrointestinal — constipation, gastrointestinal disturbance.</li><li>Respiratory — dyspnoea.</li><li>Neuropsychiatric — anxiety, sleep disturbance.</li><li>Urological — polyuria, dysuria, nocturia.</li><li>Other — oedema, lethargy, chills, nasal congestion, epistaxis, myalgia, joint swelling, sweating, rashes.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field ca206982-10cf-4c99-93c5-d616e185f784 --><!-- end item 0b6599db-45c6-47e7-8071-bf334f393056 -->","subChapters":[]},{"id":"a8a0e0c1-227a-5671-847b-ca6da3b6884e","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field a0ecb4ce-1515-440e-8935-bfa2847c875d --><h3>Drug interactions</h3><!-- end field a0ecb4ce-1515-440e-8935-bfa2847c875d -->","summary":"","htmlStringContent":"<!-- begin item ecba3423-93f7-4f05-85d5-fbb539d8f518 --><!-- begin field 03597a61-ef30-451b-b2cd-41006f6eb23a --><p><strong>Concomitant use of nifedipine is contraindicated with:</strong></p><ul><li>Rifampicin — this attenuates the effect of nifedipine.</li></ul><p><strong>Drugs that should be co-administered with caution include:</strong></p><ul><li>Other antihypertensives — nifedipine may increase their blood pressure-lowering effect.</li><li>Betablockers — deterioration of heart failure has been observed in isolated cases.</li><li>Digoxin — may lead to reduced digoxin clearance. The person should therefore be monitored for symptoms of digoxin toxicity such as confusion, nausea, anorexia, or disturbance of colour vision.<ul><li>If digoxin toxicity is suspected, measure serum digoxin levels and seek specialist advice if necessary.</li></ul></li><li>Cytochrome P450 inhibitors including macrolide antibiotics (such as erythromycin), HIV protease inhibitors (such as ritonavir), azole antimycotics (such as ketoconazole), fluoxetine, nefazodone, valproic acid, cimetidine, diltiazem, and grapefruit juice — can lead to increased plasma concentration of nifedipine.</li><li>Cytochrome P450 inducers such as phenytoin, carbamazepine, and phenobarbital — can lead to decreased plasma concentration of nifedipine.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 03597a61-ef30-451b-b2cd-41006f6eb23a --><!-- end item ecba3423-93f7-4f05-85d5-fbb539d8f518 -->","subChapters":[]},{"id":"ef8b1c21-513b-5ce0-b1d9-aff8493d1b2f","slug":"dosing-information","fullItemName":"Dosing information","depth":3,"htmlHeader":"<!-- begin field 76bea931-f7cd-45c1-b620-0914012b11a0 --><h3>Dosing information</h3><!-- end field 76bea931-f7cd-45c1-b620-0914012b11a0 -->","summary":"","htmlStringContent":"<!-- begin item d6b2772c-cb62-420e-8341-d519460c9eae --><!-- begin field a554d649-c33f-4685-ad28-175938229041 --><ul><li>A modified-release preparation should be used and the same brand prescribed for the duration of treatment to ensure consistent bioavailability.</li><li>Dosages are as recommended for non-pregnant people, and will depend on the brand used.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field a554d649-c33f-4685-ad28-175938229041 --><!-- end item d6b2772c-cb62-420e-8341-d519460c9eae -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}